TY - JOUR
T1 - A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT)
AU - Wang, Xiaobing
AU - Zhi, Xiuyi
AU - Yang, Zhaogang
AU - Tian, Haimei
AU - Li, Yanfen
AU - Li, Mo
AU - Zhao, Wenya
AU - Zhang, Chao
AU - Wang, Teng
AU - Liu, Jing
AU - Shen, Di
AU - Zheng, Cuining
AU - Zhao, Dan
AU - Yang, Sheng
AU - Qi, Jun
AU - Xin, Hongwu
AU - Stojadinovic, Alexander
AU - Avital, Itzhak
AU - Lee, L. James
AU - Rao, Jianyu
AU - Zhang, Wei
N1 - Publisher Copyright:
© Wang et al.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.
AB - Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.
KW - Biomarker
KW - Early detection
KW - Lung cancer
KW - MIC-1
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85022181996&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.17477
DO - 10.18632/oncotarget.17477
M3 - Article
AN - SCOPUS:85022181996
SN - 1949-2553
VL - 8
SP - 45345
EP - 45355
JO - Oncotarget
JF - Oncotarget
IS - 28
ER -